International Chemical Investors Group (ICIG) and the Solvay Group have entered into an agreement under which ICIG will acquire Peptisyntha SA, the Brussels, Belgium, based custom manufacturer of peptides for pharmaceutical use. Upon closing of the deal, expected later this fall, Peptisyntha will become a member of ICIG’s CordenPharma platform as its third site offering peptides manufacturing.
“With Peptisyntha, we are adding industry-leading liquid phase synthesis capabilities and a team of highly skilled staff. Together with our solid-phase, hybrid synthesis, and development capacities at our sites in Boulder, Colorado, and Liestal, Switzerland, we will be in an excellent position to offer customers the full range of peptide synthesis strategies and services”, says Christian Ewers, Chief Operating Officer of CordenPharma’s API business.
For Solvay, the divestiture marks another step in focusing on its core industrial activities, and completes the group’s exit from life science activities.
As a CordenPharma member company, Peptisyntha will continue to execute its growth strategy, serving a wide range of applications and customers. While the US sister company Peptisyntha Inc., Torrance, California, is not part of the transaction, certain of its customer relationships will be assumed by Peptisyntha in Brussels.
To read the full press release click here